Have there been tests done on liver damage from 17aa's?
- Thread starter E-Swift25
- Start date
Y
YellowJacket
Guest
Theres been one documented case steroid induced toxic hepatitis
Androgenic/Anabolic steroid-induced toxic hepatitis.
Stimac D, Miliæ S, Dintinjana RD, Kovac D, Ristiæ S
J Clin Gastroenterol 2002 Oct; 35:350-2
--------------------------------------------------------------------------------
Affiliation
Division of Gastroenterology, Department of Internal Medicine, Clinical Hospital Center Rijeka, Rijeka, Croatia. davor.stimac@ri.hinet.hr
Abstract
Athletes and bodybuilders often misuse androgenic/anabolic steroids. When used in therapeutic doses, these drugs produce clinical jaundice in just a small number of recipients. We present a 26-year-old male bodybuilder who self-administered high doses of androgenic/anabolic steroids that induced liver damage. One month before admission to the hospital, he used testosterone enanthate (500 mg intramuscularly, twice weekly), stanozolol (40 mg/d), and methylandrostenediol (30 mg/d by mouth, for 5 weeks). On admission, his bilirubin level was 470 micromol/L (direct, 360 micromol/L), his aspartate aminotransferase (AST) level was 5,870 IU/L, his alanine aminotransferase (ALT) level was 10,580 IU/L, his alkaline phosphatase (ALP) level was 152 IU/L, his gamma-glutamyl-transpeptidase level was 140 IU/L, his albumin level was 27.6 g/L, and his prothrombin time was 29%. During the patient's prolonged hospitalization, multiple tests and liver biopsy were performed, showing only toxic hepatic lesions. The patient was provided with supportive medical treatment. Clinical signs and laboratory findings improved substantially 12 weeks after the patient discontinued androgenic/anabolic steroids. The reasons for presenting this case were the much higher values of AST and ALT levels than reported in other studies, although the values of bilirubin and ALP were similar to those found in the literature. To our knowledge, it is the first case of toxic hepatitis induced by androgenic/anabolic steroids with predominantly hepatocellular necrosis instead of intrahepatic cholestasis
I think its highly overrated.
Androgenic/Anabolic steroid-induced toxic hepatitis.
Stimac D, Miliæ S, Dintinjana RD, Kovac D, Ristiæ S
J Clin Gastroenterol 2002 Oct; 35:350-2
--------------------------------------------------------------------------------
Affiliation
Division of Gastroenterology, Department of Internal Medicine, Clinical Hospital Center Rijeka, Rijeka, Croatia. davor.stimac@ri.hinet.hr
Abstract
Athletes and bodybuilders often misuse androgenic/anabolic steroids. When used in therapeutic doses, these drugs produce clinical jaundice in just a small number of recipients. We present a 26-year-old male bodybuilder who self-administered high doses of androgenic/anabolic steroids that induced liver damage. One month before admission to the hospital, he used testosterone enanthate (500 mg intramuscularly, twice weekly), stanozolol (40 mg/d), and methylandrostenediol (30 mg/d by mouth, for 5 weeks). On admission, his bilirubin level was 470 micromol/L (direct, 360 micromol/L), his aspartate aminotransferase (AST) level was 5,870 IU/L, his alanine aminotransferase (ALT) level was 10,580 IU/L, his alkaline phosphatase (ALP) level was 152 IU/L, his gamma-glutamyl-transpeptidase level was 140 IU/L, his albumin level was 27.6 g/L, and his prothrombin time was 29%. During the patient's prolonged hospitalization, multiple tests and liver biopsy were performed, showing only toxic hepatic lesions. The patient was provided with supportive medical treatment. Clinical signs and laboratory findings improved substantially 12 weeks after the patient discontinued androgenic/anabolic steroids. The reasons for presenting this case were the much higher values of AST and ALT levels than reported in other studies, although the values of bilirubin and ALP were similar to those found in the literature. To our knowledge, it is the first case of toxic hepatitis induced by androgenic/anabolic steroids with predominantly hepatocellular necrosis instead of intrahepatic cholestasis
I think its highly overrated.
slobberknocker
pro powerlifter
I've run dbol at high doses for months on end, and never had any problems.
argent
New member
This was taken from the Anadrol product insert I believe:
WARNINGS
The following conditions have been reported in patients receiving androgenic anabolic
steroids as a general class of drugs:
Peliosis hepatis, a condition in which liver and sometimes splenic tissue is replaced with
blood-filled cysts, has been reported in patients receiving androgenic anabolic steroid
therapy. These cysts are sometimes present with minimal hepatic dysfunction, but at
other times they have been associated with liver failure. They are often not recognized
until life-threatening liver failure or intra-abdominal hemorrhage develops. Withdrawal
of drug usually results in complete disappearance of lesions.
Liver cell tumors are also reported. Most often these tumors are benign and androgendependent,
but fatal malignant tumors have been reported. Withdrawal of drug often
results in regression or cessation of progression of the tumor. However, hepatic tumors
associated with androgens or anabolic steroids are much more vascular than other hepatic
tumors and may be silent until life-threatening intra-abdominal hemorrhage develops.
Blood lipid changes that are known to be associated with increased risk of
atherosclerosis are seen in patients treated with androgens and anabolic steroids. These
changes include decreased high density lipoprotein and sometimes increased low density
lipoprotein. The changes may be very marked and could have a serious impact on the risk
of atherosclerosis and coronary artery disease.
Cholestatic hepatitis and jaundice occur with 17-alpha-alkylated androgens at
relatively low doses. Clinical jaundice may be painless, with or without pruritus. It may
also be associated with acute hepatic enlargement and right upper-quadrant pain, which
has been mistaken for acute (surgical) obstruction of the bile duct. Drug-induced jaundice
is usually reversible when the medication is discontinued. Continued therapy has been
associated with hepatic coma and death. Because of the hepatoxicity associated with
oxymetholone administration, periodic liver function tests are recommended.
In patients with breast cancer, anabolic steroid therapy may cause hypercalcemia by
stimulating osteolysis. In this case, the drug should be discontinued.
Edema with or without congestive heart failure may be a serious complication in
patients with pre-existing cardiac, renal or hepatic disease. Concomitant administration
with adrenal steroids or ACTH may add to the edema. This is generally controllable with
appropriate diuretic and/or digitalis therapy.
DOSAGE AND ADMINISTRATION
The recommended daily dose in children and adults is 1-5 mg/kg body weight per day.
The usual effective dose is 1-2 mg/kg/day but higher doses may be required, and the dose
should be individualized. Response is not often immediate, and a minimum trial of three
to six months should be given. Following remission, some patients may be maintained
without the drug; others may be maintained on an established lower daily dosage. A
continued maintenance dose is usually necessary in patients with congenital aplastic
anemia.
WARNINGS
The following conditions have been reported in patients receiving androgenic anabolic
steroids as a general class of drugs:
Peliosis hepatis, a condition in which liver and sometimes splenic tissue is replaced with
blood-filled cysts, has been reported in patients receiving androgenic anabolic steroid
therapy. These cysts are sometimes present with minimal hepatic dysfunction, but at
other times they have been associated with liver failure. They are often not recognized
until life-threatening liver failure or intra-abdominal hemorrhage develops. Withdrawal
of drug usually results in complete disappearance of lesions.
Liver cell tumors are also reported. Most often these tumors are benign and androgendependent,
but fatal malignant tumors have been reported. Withdrawal of drug often
results in regression or cessation of progression of the tumor. However, hepatic tumors
associated with androgens or anabolic steroids are much more vascular than other hepatic
tumors and may be silent until life-threatening intra-abdominal hemorrhage develops.
Blood lipid changes that are known to be associated with increased risk of
atherosclerosis are seen in patients treated with androgens and anabolic steroids. These
changes include decreased high density lipoprotein and sometimes increased low density
lipoprotein. The changes may be very marked and could have a serious impact on the risk
of atherosclerosis and coronary artery disease.
Cholestatic hepatitis and jaundice occur with 17-alpha-alkylated androgens at
relatively low doses. Clinical jaundice may be painless, with or without pruritus. It may
also be associated with acute hepatic enlargement and right upper-quadrant pain, which
has been mistaken for acute (surgical) obstruction of the bile duct. Drug-induced jaundice
is usually reversible when the medication is discontinued. Continued therapy has been
associated with hepatic coma and death. Because of the hepatoxicity associated with
oxymetholone administration, periodic liver function tests are recommended.
In patients with breast cancer, anabolic steroid therapy may cause hypercalcemia by
stimulating osteolysis. In this case, the drug should be discontinued.
Edema with or without congestive heart failure may be a serious complication in
patients with pre-existing cardiac, renal or hepatic disease. Concomitant administration
with adrenal steroids or ACTH may add to the edema. This is generally controllable with
appropriate diuretic and/or digitalis therapy.
DOSAGE AND ADMINISTRATION
The recommended daily dose in children and adults is 1-5 mg/kg body weight per day.
The usual effective dose is 1-2 mg/kg/day but higher doses may be required, and the dose
should be individualized. Response is not often immediate, and a minimum trial of three
to six months should be given. Following remission, some patients may be maintained
without the drug; others may be maintained on an established lower daily dosage. A
continued maintenance dose is usually necessary in patients with congenital aplastic
anemia.
slobberknocker
pro powerlifter
A minimum of 3 months on drol, at 1mg/kg/day. So a 150 lbs person = about 70 kg. 50-100mg drol for a minimum of 3 months. Interesting.
